Table 3 Overview of prevalence of specific mutations specified for each molecular diagnosis
From: Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics
Molecular diagnosis | TP53 | FUBP1 | CIC | ATRX | PTEN | NOTCH1 | PIK3CA |
|---|---|---|---|---|---|---|---|
n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
Astrocytoma | 114 (97.4) | 1 (0.9) | 3 (2.6) | 85 (72.6) | 6 (5.1) | 9 (7.7) | 1 (0.9) |
Oligodendroglioma | 3 (5.6) | 15 (27.8) | 26 (48.1) | 2 (3.7) | 5 (9.3) | 7 (13.0) | 3 (5.6) |
Glioblastoma | 45 (25.1) | 0 (0) | 7 (3.9) | 6 (3.4) | 81 (45.3) | 8 (4.5) | 2 (1.1) |
H3F3A K27 M-mutated tumor | 7 (77.8) | 1 (11.1) | 0 (0) | 1 (11.1) | 1 (11.1) | 1 (11.1) | 1 (10.0) |
H3F3A G34 M-mutated tumor | 3 (100) | 0 (0) | 1 (33.3) | 3 (100) | 0 (0) | 0 (0) | 0 (0) |
BRAF-mutated tumor | 1 (6.7) | 1 (6.7) | 1 (6.7) | 0 (0) | 0 (0) | 1 (6.7) | 1 (6.7) |
Unclassifying mutations | 10 (27.0) | 1 (2.7) | 1 (2.7) | 7 (18.9) | 8 (21.6) | 3 (8.1) | 2 (5.4) |